ReviewCancer metastasis reviews2025
Functions and clinical implications of the liver microenvironment in hepatic uveal melanoma metastases.
Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting liver metastases in uveal melanoma: ATX-LPA mediated immunosuppression and novel therapeutic approaches.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Uveal melanoma (UM) is an aggressive intraocular malignancy in adults arising from the melanocytes of the uveal tract. While primary UM lesions can be successfully treated, ~ 50% of UM patients develop metastases primarily in the liver. Patients with liver metastatic UM (LMUM) have poor prognosis and few therapeutic options. LMUM lesions are unresponsive to standard chemotherapies, targeted therapies, and immune checkpoint inhibitors - an effect at least in part associated with the detoxification function of the liver and the diverse hepatic immunological landscape. Here, we recount the etiology and molecular mechanisms in the development of LMUM, examine the influences of the hepatic tumor microenvironment (TME) on UM liver tropism, and review how the innate and peripheral immune response contributes to LMUM progression and therapeutic efficacy. The unique immunological properties of the liver coupled with the distinct growth patterns of LMUM lesions present significant challenges for developing effective treatments that can overcome this specialized microenvironment. Improved understanding of the interplay between the liver and LMUM is essential for the development of more effective diagnostic techniques and improved therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.